



---

## **A Revolutionary Toothpaste Based Approach To Food Allergy Immunotherapy**

Series B



## Our mission



INTROMMUNE is developing *safe* and *effective* options for food allergy sufferers so that they and their loved ones can live their lives *without fear*



# Food allergies are a rising concern with limited options

Food allergies affect **32mm** Americans  
(220mm+ worldwide)



Total cost of childhood food allergies -  
**\$25B/year**



**9** common foods account for over  
**90%** of all food allergies



The **oral cavity** is the natural classroom where the  
body learns its relationship with food



Current *best* option is **avoidance**



Intromune's first product will address peanut  
allergies



# Introducing a novel approach to allergy desensitization


Delivering therapeutic agents through oral mucosal immunotherapy (OMIT)




Embedded food derived  
allergen proteins



Administered at the same time  
patients brush their teeth




Convenient daily  
immunotherapy




## Intrommune toothpaste delivers allergen protein

Toothpaste slurry coats the mouth so more allergen protein can bind with cells on the surface of the oral mucosal epithelium. The opposing charges of the protein and surface cells attracts them to each other to form a strong bond.








## Langerhans Cells process and display allergen proteins

Oral Langerhans cells capture allergen protein as it diffuses into the oral mucosa, displaying key identifiers on their surface before travelling to regional lymph nodes.





## Oral Mucosal Epithelium



## Langerhan cells trigger the re-education of the immune system


Once in the regional lymph nodes Langerhans cells activate naive T cells causing them to differentiate into either T regulatory (Treg) cells or T helper type 1 (Th1) cells.





## Differentiated T Cells decrease the allergic response

Treg and Th1 cells travel through lymph vessels and distribute themselves throughout the mucosa of the aerodigestive tract where they decrease the allergic immune response the next time there is exposure to the specific allergen protein.





# OMIT – Peanut key investment metrics

## OPPORTUNITY



**6M**

U.S. Peanut  
Allergic Pop



**1.6M**

U.S. Peanut  
Allergic Children



**1M**

Diagnosed  
(Aged 4 – 18 years)



**690K**

Immediate  
serviceable market  
for Intromune\*

## UNMET NEED

TAM:  
**\$7,369,200,000**

Insurance Coverage:  
**Yes**

OIT Price/Year Per Patient:  
**\$10,680**

### Solutions / Expectations

- ✓ Reduce adverse effects
- ✓ Better adherence
- ✓ Synergies
- ✓ Multi-product platform

# Intellectual property



Exclusive global IP  
license for food  
allergy  
immunotherapy



Global portfolio  
*(Including U.S., EU, China,  
India, Japan)*



Two patent families  
– 35 *patents* to date

- Toothpaste + allergens for immunotherapy
- Formulations to stabilize allergens



Global protection  
through 2034

- Potential to extend to 2041



Additional IP grants  
expected, and new  
filings planned

# Intromune OMIT: A clinically de-risked biotech opportunity



INTROMMUNE  
THERAPEUTICS



100,000 new peanut allergy (PA) sufferers in the U.S. per year (\$1B new market entrants)



Substantial upside with multiple near-term liquidity events



Low development risk



Patients/Practitioners/Payers seeking *protection* from accidental exposure



Significant social impact



Multi-product / licensing opportunities



Significant improvement over comparators - comp acquired for \$2.6B

# Intromune Peanut OMIT — Clear approval pathway

Phase 1b Study  
Underway  
(INT301-101)



CRO engaged — Circuit Clinical

IND filed & accepted



Highly collaborative

No toxicology review (API is peanut protein)

No pharmacokinetics due to route of administration

No animal models

# Milestones & goals

## Series A \$3.7mm

### INVESTORS:

Robin Hood Ventures / Rowan  
Innovation / Argonne Capital /  
Timberline Holdings / Chemical  
Angel Network / Red Bear Angels

### ACCOMPLISH:

- Exclusive OMIT rights for food allergy
- Developed INT301 formulation
- IND accepted
- Phase 1 b

### INVESTORS:

Focus on strategic partners  
(investors), private capital, and  
venture

### GOALS:

- Launch Phase 2 (2022)
- Chemistry, Manufacturing & Controls (CMC) implementation
- Continue reconstituting management and advisory board
- Media and professional branding / marketing push
- Identify liquidity and market opportunities

## Series B \$20mm



## Valuation projections: post-phase 1b

Target Valuation:  
**\$300-400mm**

Expected target *6 months*

With significant upside:

- Safe, simple and controlled manufacture
- Positive *social* and *health* impact
- Numerous *synergies* and *partnerships*



Valuation: **\$145mm**

- Complicated manufacturing
- No public comparables at time
- Limited evidence of efficacy



Valuation: **\$300mm**

with additional 10% royalties

- DNA vaccine – high risk
- Potential for germline effects



## Valuation projections: post-phase 2

Target Valuation:  
**\$1B+**

Expected target H1 2023

With significant upside:

- Numerous *synergies* and *partnerships*
- Expectation for multi-allergen innovation with parallel development tracks



Valuation: **\$4B+**

- Believed to have received multiple offers when considered a safe and effective alternative
- Regulatory complications



Valuation: **\$650mm**

- Known high risks
- Epinephrine use, GI and EoE
- Inefficient application



# Key comparator – Aimmune Therapeutics

OMIT makes lifelong usage easy *without* the adverse events observed with OIT



Acquired for \$2.6B

- OIT technology with *NO current revenue*
- *Inconvenient delivery*
  - Patients must add peanut powder to semi-solid food daily
- *Significant adverse event profile*
  - *Increased* systemic allergic reactions
  - *Increased* discontinuation due to AEs
  - *Increased* reports of EoE (chronic, allergic inflammatory disease)
- *Restrictive REMS* (Risk Evaluation and Mitigation Strategy)
- *Increases risk* of emergency epinephrine requiring ER visit
- Many patients will have to take product for life

# Key comparator – DBV Technologies

OMIT is the *only* safe and effective immunotherapy under development



\$600mm valuation

*EPIT* technology received an FDA complete response letter

- Skin patch containing peanut proteins *irritates* skin
- Issues with *patch adhesion*
- *Reworking* of CMC required
- Continued extended *delay*, approval uncertain
- Corporate *restructuring* occurring, *making talent available*
- *Efficacy low*
  - 2 years of constant use before protection potentially achieved
  - Phase 3 efficacy endpoint missed

# Management



Michael Nelson, JD  
CEO



Erick Berglund, PhD.  
CSO



Michelle Mantia  
Operations Manager



Alain Van Loo  
COO



Keith James, MBA CPA  
CFO



Abhit Singh, MD  
VP MA

## Advisory Board

William Reisacher, MD | Inventor of OMIT; Senior Scientific Advisor, Chair

Greg Plunkett, PhD | CMC Advisor

Anthony Robinson, CRNP, MBA | Clinical Advisor

Tonya Winders, MBA | Stakeholder Outreach Advisor

Terrence Tormey | Business Development Advisor

Jotin Marango, MD, PhD | Corporate Development & Finance Advisor, Chair

Greg Van Gasse, MBA | Marketing Advisor

Jack Levitt, MBA | Executive Development Advisor

David Sanders | Government Affairs Advisor

Mark Durham | Human Capital Advisor



# Intromune opportunity at-a-glance



Revolutionary *patented* commercial grade *toothpaste* drug-delivery platform



Current product name:  
*Peanut INT301*



Greater *efficacy* expected

- 12x mucosal coverage in comparison to SLIT
- Targets *entire* oral cavity surface
- Contacts more *optimal* areas of mouth
- *Dosing* >2mg (2mg = 300mg OIT)



Expected to be *safe*, no epinephrine use



Built-in adherence with daily routine

- *No adverse taste* or difficulty in administration
- Reinforces *positive habits* – oral health
- *Reduces anxiety* / Don't have to feel afflicted



*Platform* for multiple food allergy treatments

# Disclosures



## Important Information

The information regarding the proposed private placement offering by Intrimmune Therapeutics is being provided to you on a confidential basis only and should not be disclosed to anyone other than your professional advisers on a confidential basis for purposes related to your interest in the company. This information should not be divulged, reproduced or disseminated without our consent.

Only qualified “accredited investors” as defined in Regulation D under the Securities Act of 1933, as amended will be permitted to participate in the proposed offering. Additional suitability requirements may apply.

These materials do not constitute either an offer to sell or an offer to purchase securities. Any purchase of securities will be made pursuant to and governed by a subscription agreement between the company and the investor, and the company will have the right to accept or reject subscriptions in its sole discretion. There is no minimum amount of subscriptions we must receive before we close on any subscription.

We will make available to any prospective purchaser and such person’s advisers the opportunity to ask questions and receive answers concerning the terms and conditions of the proposed offering, the company, or any other relevant matters, and to obtain any additional information to the extent the company possesses such information.

Any investment in Intrimmune Therapeutics involves a high degree of risk. You should carefully read all of the risk factors attached to the subscription agreement prior to any investment. There is no assurance that an investment will be profitable at any time.

Neither Intrimmune Therapeutics nor any of its equity interests are registered with the Securities and Exchange Commission or the securities regulator of any state.


This communication contains forward looking-statements, which can be identified by, among other things, the use of forward-looking language, such as the words “plans,” “intends,” “believes,” “expects,” “anticipates,” “estimates,” “projects,” “potential,” “may,” “will,” “would,” “could,” “should,” “seeks,” or “scheduled to,” or other similar words, or by discussion of strategy or intentions. Forward-looking statements are based upon management’s present expectations or strategies regarding the future and are subject to known and unknown risks and uncertainties that could cause actual results, events or developments to be materially different from those indicated in such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. The information contained herein and in the documents enclosed herewith is current only as of the date hereof and you should not, under any circumstances, assume that there has not been any change in the matters discussed herein or in the documents enclosed herewith since the date hereof.




## Appendix

# OMIT targets entire oral mucosa

Exposure to oral immune cells optimized with OMIT



## OMIT Toothpaste Tissue Contact



Number of LCs in different anatomical locations of the oral cavity